Facebook Pixel

ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio
GRACEcast Lung Cancer Audio

Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.

GRACEcast Lung Cancer Audio
Not playing